Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Cardiovasc Revasc Med ; 20(2): 143-146, 2019 02.
Article in English | MEDLINE | ID: mdl-29807815

ABSTRACT

BACKGROUND: Fractional flow reserve(FFR) is a validated tool for evaluating functional severity and guiding the revascularization of angiographically moderate coronary artery lesions. OBJECTIVE: To study if there is a higher frequency of positive FFR measurements in the left anterior descending(LAD) versus other major coronary arteries and also evaluate the differences in the total length of the stent placed. METHODS: A retrospective cohort study including all subjects (January 2011 to December 2015) who had fractional flow reserve (FFR) measured during coronary catheterization was conducted. Coronary catheterizations with FFR at a single tertiary care center were reviewed and FFR ≤ 0.80 post adenosine was deemed positive. The differences in the baseline characteristics and the degree of stenosis were compared between the different vessel groups. RESULTS: Of the 758 vessels included in the analysis, the majority were LAD(51.3%) followed by right coronary artery(RCA)(22.8%), Circumflex(22.2%), Left main(2.2%), and Ramus intermedius(1.5%). 25.1% of 758 vessels were FFR positive. The proportion of positive FFR were higher among LAD versus other vessels(33.2%vs.16.5%,p < 0.001), while no differences were noted between RCA and circumflex(p = 0.87) or other vessels excluding LAD(p = 0.69). Of 175 patients who received stents, no statistical difference was noted in the median[range] total length of the stent between LAD(22[9-64]) and the other coronary arteries (18[8-42])(p = 0.19). In patients with an FFR <0.75, we found that the stent length(median [range]) was significantly longer in LAD(28[9-42]) than the other coronary arteries(18[8-42])(p = 0.03). CONCLUSION: In our study, FFR was almost twice as likely to be positive in the LAD when compared to other major coronary arteries. Furthermore, there was a trend towards FFR positive LAD lesions needing longer stents than other coronary arteries. This data should encourage operators to evaluate moderate, long lesions in the LAD with FFR, as they have a higher probability of functional significance.


Subject(s)
Cardiac Catheterization , Coronary Artery Disease/diagnosis , Coronary Stenosis/diagnosis , Coronary Vessels/physiopathology , Fractional Flow Reserve, Myocardial , Aged , Coronary Artery Disease/physiopathology , Coronary Artery Disease/therapy , Coronary Stenosis/physiopathology , Coronary Stenosis/therapy , Databases, Factual , Female , Humans , Male , Middle Aged , Percutaneous Coronary Intervention/instrumentation , Predictive Value of Tests , Retrospective Studies , Stents , Treatment Outcome
2.
Rev Cardiovasc Med ; 19(2): 41-49, 2018 Jun 30.
Article in English | MEDLINE | ID: mdl-31032602

ABSTRACT

In this systematic review, we sought to summarize the 3 recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials (Dapagliflozin Effect on CardiovasculAR Events (DECLARE-TIMI 58), Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, and Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)) and to explore the potential causes for their different results. We found that the major adverse cardiovascular event rates per 1000 patient-years for drug and placebo, as well as the corresponding relative risk reductions, were 22.6, 24.2, 7%; 26.9, 31.5, 14%; 37.4, 43.9, 14% for DECLARE-TIMI 58, CANVAS, and EMPA-REG OUTCOME, respectively. DECLARETIMI 58 had the fewest cardiorenal events (across treatment and control arms) and EMPA-REG OUTCOME the most. DECLARE-TIMI 58 used alternative inclusion criterion for baseline renal function (creatinine clearance ≧ 60 mL/min) compared to the other trials (estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2 bodysurface area). Therefore, the DECLARE-TIMI 58 study cohort had higher eGFR (mean eGFR 85.2 mL/min/1.73 m2 compared to 76.5 and 74 in CANVAS and EMPAREG OUTCOME, respectively); this may have caused the difference in results. Additionally contributing to the high event rate in EMPA-REG OUTCOME was the requirement of prior confirmed cardiovascular disease (CVD), resulting in 99.2% of patients with CVD compared to only 65.6% and 40.6% in CANVAS and DECLARE-TIMI 58, respectively (which did not require CVD). In conclusion, there is a need for large-scale studies of SGLT2i with matching inclusion/exclusion criteria and appropriate endpoints to ensure a truly direct comparison of the drugs.


Subject(s)
Benzhydryl Compounds/therapeutic use , Canagliflozin/therapeutic use , Cardiovascular Diseases/physiopathology , Diabetes Mellitus, Type 2/drug therapy , Glucosides/therapeutic use , Kidney Diseases/physiopathology , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Benzhydryl Compounds/adverse effects , Biomarkers , Blood Glucose/drug effects , Blood Glucose/metabolism , Canagliflozin/adverse effects , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/mortality , Cause of Death , Comorbidity , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/metabolism , Glucosides/adverse effects , Health Status , Humans , Kidney Diseases/diagnosis , Kidney Diseases/mortality , Randomized Controlled Trials as Topic , Research Design , Risk Factors , Sodium-Glucose Transporter 2/drug effects , Sodium-Glucose Transporter 2/metabolism , Sodium-Glucose Transporter 2 Inhibitors/adverse effects , Treatment Outcome
3.
Rev Cardiovasc Med ; 19(2): 51-63, 2018 Jun 30.
Article in English | MEDLINE | ID: mdl-31032603

ABSTRACT

Clinical trials of sodium glucose co-transporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and comorbid cardiovascular and kidney disease have shown reductions in major adverse cardiovascular events, heart failure hospitalizations, and attenuation of the progression of kidney disease. The magnitude of benefit appears to be greater than expected due to glycemic control, reduced blood pressure, and loss of adiposity. This impact is also independent from reduced renal function and lesser degrees of natriuresis and glycosuria. However, these agents have also been associated with limb amputation, Fournier's gangrene, diabetic ketoacidosis, metabolic bone disease, and increased hematopoiesis. A strong off-target effect of SGLT2i on the sodium-proton antiporter (exchanger) on the cell surface and intracellular organelles explains the wide-ranging effects of these agents. By slowing the restoration of pH within cells, SGLT2i activate secondary processes that mimic ischemic preconditioning in the heart and kidney and increased hematopoiesis in bone marrow which would explain salutary effects. Conversely, the inability to rapidly recover pH in ischemic peripheral tissues explains the progression of diabetic extremity ulcers, gangrene, propensity for metabolic bone disease, and diabetic ketoacidosis in patients who are predisposed. This paper will review the evidence for the strong off-target effect of SGLT2i on the sodium-proton exchanger and its potential effect on the organ systems and processes in which SGLT2i appear to have activity.


Subject(s)
Cardiovascular Diseases/metabolism , Cardiovascular System/drug effects , Diabetes Mellitus, Type 2/drug therapy , Kidney Diseases/metabolism , Kidney/drug effects , Sodium-Glucose Transporter 2 Inhibitors/adverse effects , Sodium-Hydrogen Exchangers/antagonists & inhibitors , Animals , Biomarkers , Blood Glucose/drug effects , Blood Glucose/metabolism , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/mortality , Cardiovascular Diseases/physiopathology , Cardiovascular System/metabolism , Cardiovascular System/physiopathology , Comorbidity , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/mortality , Health Status , Humans , Hydrogen-Ion Concentration , Kidney/metabolism , Kidney/physiopathology , Kidney Diseases/diagnosis , Kidney Diseases/mortality , Kidney Diseases/physiopathology , Risk Factors , Sodium-Glucose Transporter 2/drug effects , Sodium-Glucose Transporter 2/metabolism , Sodium-Hydrogen Exchangers/metabolism , Treatment Outcome
4.
Catheter Cardiovasc Interv ; 87(7): 1333-1337, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26105577

ABSTRACT

The MitraClip® has increasing use for severe, high surgical risk mitral regurgitation (MR). The MitraClip® is implanted percutaneously across the interatrial septum. Given the large diameter of the device delivery system, the femoral vein is the best option for central venous access. This is the first reported case of successful MitraClip® implantation through a chronically occluded IVC filter. © 2015 Wiley Periodicals, Inc.

5.
Am J Cardiol ; 116(8): 1298-303, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26307174

ABSTRACT

In 2009, we described morphologic findings in 22 patients having resection of an ascending aortic aneurysm in the previous 11 years at the Baylor University Medical Center, and histologic examination of the aneurysmal wall disclosed classic findings of syphilitic aortitis. The major purpose of that extensively illustrated report was to describe the characteristic gross features of the aneurysm such that syphilitic aortitis might be better recognized at operation and appropriate antibiotics administered postoperatively. The aim of the present study was to emphasize that syphilis remains a major cause of ascending aortic aneurysm. From January 1, 2009, to December 31, 2014, we studied additional 23 patients who had resection of an ascending aortic aneurysm that again histologically had classic features of syphilitic aortitis. All 23 patients were found to have syphilitic aortitis grossly and histologically. The aneurysm involved the ascending portion of aorta in all 23, the arch portion in 12, and the descending thoracic portion in 10. In conclusion, syphilis has far from disappeared. It remains a major cause of ascending aortic aneurysm.


Subject(s)
Aortic Aneurysm, Thoracic/diagnosis , Aortic Aneurysm, Thoracic/microbiology , Syphilis, Cardiovascular/complications , Adult , Black or African American , Aged , Aged, 80 and over , Aortic Aneurysm, Thoracic/surgery , Asian , Body Mass Index , Cohort Studies , Female , Humans , Male , Middle Aged , Risk Factors , Syphilis, Cardiovascular/diagnosis , Syphilis, Cardiovascular/ethnology , White People
6.
Am J Cardiol ; 116(8): 1311-4, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26294135

ABSTRACT

This report describes certain computed tomographic and morphologic features of syphilitic aortitis in 2 patients in whom the process involved the entire thoracic aorta.


Subject(s)
Aortitis/diagnostic imaging , Aortitis/pathology , Syphilis, Cardiovascular/diagnostic imaging , Syphilis, Cardiovascular/pathology , Aged , Fatal Outcome , Female , Humans , Male , Tomography, X-Ray Computed
7.
Am J Cardiol ; 116(6): 973-6, 2015 Sep 15.
Article in English | MEDLINE | ID: mdl-26209115

ABSTRACT

Electrocardiographic voltage has been used to determine the presence of left ventricular hypertrophy for about 70 years. Varying electrocardiographic criteria have been applied. We have found total 12-lead QRS voltage to be most useful in this regard. We measured total 12-lead QRS voltage in 24 patients in whom an ascending aortic aneurysm was resected and histologic study of its wall was classic of syphilitic aortitis. In these 24 patients total 12-lead QRS voltage ranged from 57 to 161 mm, averaging 120 ± 32 in the 11 men and 106 ± 24 mm in the 13 women. If normal 12-lead QRS voltage in adults is considered to be >175 mm not a single one of the 24 patients had normal voltage. Indeed, most were in the low normal area. Thus, this study provides some evidence via this indirect means that the heart itself is infrequently involved by syphilitic aortitis which produces an ascending aortic aneurysm of sufficient size to warrant resection.


Subject(s)
Aneurysm, Infected/physiopathology , Aortic Aneurysm, Thoracic/physiopathology , Aortitis/physiopathology , Electrocardiography , Syphilis, Cardiovascular/physiopathology , Adult , Aged , Aged, 80 and over , Aneurysm, Infected/surgery , Aortic Aneurysm, Thoracic/surgery , Aortitis/surgery , Cohort Studies , Female , Humans , Male , Middle Aged , Syphilis, Cardiovascular/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...